EVALI and the Pulmonary Toxicity of Electronic Cigarettes: A Review.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 32246394.
- Also identified by DOI 10.1007/s11606-020-05813-2 and PMC identifier 7351931.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Electronic cigarettes are a novel and emerging product increasingly used by the general public. However, despite their popularity, they remain poorly studied and with likely serious health risks. EVALI, or "electronic cigarette or vaping product use-associated lung injury," is a recently described entity at the forefront of current investigations. Though EVALI has been linked to vitamin E acetate, a constituent of THC vaping products, electronic cigarettes likely pose a host of other pulmonary toxicities. The presentation, diagnostic work-up, treatment, and pathophysiology of EVALI are herein described, as well as the general pulmonary toxicity profile of electronic cigarettes.
Medical subject headings
- Drug-Related Side Effects and Adverse Reactions
- Electronic Nicotine Delivery Systems
- Lung Injury
- Vaping